← Back to Search

Taxane

Tesetaxel once every 3 weeks for Prostate Cancer

Phase 2
Waitlist Available
Led By Michael J Morris, MD
Research Sponsored by Genta Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

Given the activity of docetaxel in patients with progressive, metastatic castration-resistant prostate cancer, this study is being undertaken to evaluate the activity of tesetaxel, an orally bioavailable taxane, in chemotherapy-naive and chemotherapy-exposed patients.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2014 Phase 2 trial • 17 Patients • NCT01064713
23%
fatigue
15%
anorexia
15%
vomiting
15%
constipation
15%
muscle weakness
15%
taste alteration
15%
nausea
8%
peripheral neuropathies
8%
stomatitis
8%
chills
8%
headaches
8%
diarrhea
8%
pain
8%
heartburn
100%
80%
60%
40%
20%
0%
Study treatment Arm
40 Tesetaxel, Cohort A
50 mg Tesetaxel, Cohort B

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Tesetaxel once every 3 weeksExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tesetaxel
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Genta IncorporatedLead Sponsor
30 Previous Clinical Trials
1,613 Total Patients Enrolled
Michael J Morris, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
3 Previous Clinical Trials
452 Total Patients Enrolled
1 Trials studying Prostate Cancer
385 Patients Enrolled for Prostate Cancer
~4 spots leftby Nov 2025